Drug Profile
Research programme: cancer and HIV biotherapies - InnaVirVax
Alternative Names: IVV001; STOP3SLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator InnaVirVax
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; HIV infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in France
- 16 Jul 2016 No recent reports of development identified for research development in HIV-infections in France
- 16 Jul 2010 Early research in Cancer in France (unspecified route)